Core Viewpoint - Crinetics Pharmaceuticals, Inc. has announced a public offering of 7,620,000 shares at a price of $45.95 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consists entirely of shares sold by Crinetics, with a 30-day option for underwriters to purchase an additional 1,143,000 shares [1]. - The expected closing date for the offering is around January 8, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for commercial activities related to the launch of PALSONIFY™, R&D of product candidates, and general corporate purposes, including capital expenditures and working capital [2]. - Crinetics may also consider using a portion of the proceeds for in-licensing, acquiring, or investing in complementary businesses or technologies, although there are no current commitments to do so [2]. Group 3: Company Overview - Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [6]. - The company's lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the FDA for adults with acromegaly who have not responded adequately to surgery [7]. - Crinetics has a pipeline of over 10 disclosed programs, including candidates for congenital adrenal hyperplasia and neuroendocrine tumors, addressing various endocrine conditions [7].

Core Insights - Crinetics Pharmaceuticals, Inc. is preparing to host a conference call on January 5, 2026, to discuss the commercialization of PALSONIFY, the first FDA-approved oral treatment for acromegaly, and to share results from the Phase 2 trial of atumelnant for congenital adrenal hyperplasia [1][6] Group 1: Company Overview - Crinetics focuses on developing treatments for endocrine diseases, utilizing small molecules that target G-protein coupled receptors (GPCRs) [2] - The company's pipeline includes atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as CRN09682 for SST2 expressing tumors [2] Group 2: Financial Performance - Evercore ISI has maintained an "Outperform" rating for CRNX, raising the price target from $80 to $90, despite the stock price being $52.57 and a negative price-to-earnings (P/E) ratio of -10.29 [3] - The company has a high price-to-sales ratio of 2,856.31 and an elevated enterprise value to sales ratio of 2,816.08, indicating that investors are paying a premium for its sales [4] - Crinetics has a negative earnings yield of -9.72%, but maintains a low debt-to-equity ratio of 0.046, reflecting minimal reliance on debt [5] - The company exhibits a strong liquidity position with a current ratio of 15.12, indicating it can comfortably cover its short-term liabilities [5]

Group 1 - Crinetics Pharmaceuticals will host a conference call and webcast on January 5, 2026, to provide updates on PALSONIFY™ commercialization and disclose topline results from the Phase 2 trial of atumelnant [1][2] - PALSONIFY™ (paltusotine) is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [4] - Crinetics has a deep pipeline of over 10 disclosed programs, including atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682 for treating SST2 expressing neuroendocrine tumors [4] Group 2 - Crinetics Pharmaceuticals focuses on transforming the treatment of endocrine diseases and related tumors through patient-centered science [3] - The company specializes in discovering, developing, and commercializing novel therapies targeting G-protein coupled receptors (GPCRs) with tailored pharmacology [3]

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Cr ...

Core Viewpoint - Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is recognized by Wall Street analysts as a promising biotech stock, with expectations for significant growth in 2026 due to the launch of key drugs [1][2]. Group 1: Company Overview - Crinetics Pharmaceuticals is a clinical-stage drug company focused on developing oral treatments for rare endocrine diseases and tumors, including acromegaly, Cushing's disease, carcinoid syndrome, and congenital adrenal hyperplasia (CAH) [5]. - The company utilizes small molecules and peptide agonists that target hormone receptors in its drug development efforts [5]. Group 2: Pipeline and Research - The company is currently conducting the BRAVESST2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682, a drug developed from its nonpeptide drug conjugate (NDC) platform [3]. - The first patient has been dosed in Phase ½ of the study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors [2]. Group 3: Financial Position - Crinetics is in a strong financial position, with more cash than debt on its balance sheet, which allows the company to accelerate its pipeline development [3]. Group 4: Leadership Insight - Stephen Betz, Chief Scientific Officer and Co-Founder of Crinetics, emphasized that CRN09682 was developed to meet the need for a more efficacious, safer, and convenient targeted therapy for patients with SST2-expressing tumors [4].

Core Insights - Crinetics Pharmaceuticals has initiated a Phase 1/2 clinical trial for CRN09682, targeting SST2-positive neuroendocrine tumors and other solid tumors, marking a significant milestone for the company's nonpeptide drug conjugate platform [1][2] Company Overview - Crinetics Pharmaceuticals is focused on transforming the treatment of endocrine diseases and related tumors, leveraging expertise in G-protein coupled receptors (GPCRs) and small molecule design [5] - The company has a deep pipeline of over 10 disclosed programs, including PALSONIFY™ (paltusotine), which is the first oral treatment approved by the U.S. FDA for acromegaly [6][7] Drug Development - CRN09682 is a first-in-class, non-radioactive, nonpeptide drug conjugate designed to selectively bind to SST2-expressing tumor cells, releasing a potent cytotoxic agent, monomethyl auristatin E (MMAE), directly within the tumor [4] - The Phase 1/2 BRAVESST2 trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682, with up to 150 participants expected to be enrolled [3] Clinical Trial Details - The trial consists of a dose-escalation study to determine the maximum tolerated dose and a dose expansion phase to further evaluate CRN09682 in selected SST2-expressing tumor types [3] - Eligible patients must have metastatic or locally advanced disease progression following standard therapies, confirmed by somatostatin receptor imaging [3]

Core Insights - Crinetics Pharmaceuticals has initiated the pivotal Phase 3 CAREFNDR trial to evaluate the efficacy and safety of paltusotine for treating carcinoid syndrome associated with neuroendocrine tumors, building on positive Phase 2 results [1][2][3] Company Overview - Crinetics Pharmaceuticals is focused on developing transformative therapies for endocrine diseases and related tumors, with a core expertise in targeting G-protein coupled receptors [7][8] - The company’s lead product, paltusotine, is the first once-daily oral treatment approved for adults with acromegaly who have had an inadequate response to surgery [8] Clinical Trial Details - The CAREFNDR trial will enroll 141 adults with carcinoid syndrome, randomizing participants in a 2:1 ratio to receive either paltusotine 80 mg or a matching placebo [2] - The primary endpoint of the trial is to measure the change in flushing episodes per day from baseline to Week 12, with bowel movement frequency as a key secondary endpoint [2] - Following the 16-week randomized period, the trial includes a 104-week open-label extension to evaluate long-term efficacy and safety [2] Product Information - Paltusotine is a selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide currently in Phase 3 development for carcinoid syndrome, showing rapid and sustained reductions in symptoms during Phase 2 trials [5][6] - Approximately 20% of patients with neuroendocrine tumors experience carcinoid syndrome, characterized by symptoms such as diarrhea and flushing [6] Future Development - Crinetics is also exploring additional treatment options for neuroendocrine tumors through CRN09682, an investigational anti-tumor candidate that has received Investigational New Drug clearance [3]

Core Insights - Crinetics Pharmaceuticals is presenting new data on paltusotine, a novel SST2 agonist, at the NANETS 2025 meeting, highlighting its potential anti-tumor effects in treating carcinoid syndrome associated with neuroendocrine tumors (NETs) [1][2] - The Phase 2 study of paltusotine shows a promising one-year progression-free survival rate of 74% in patients with carcinoid syndrome [2][4] - Paltusotine is currently approved in the U.S. for treating acromegaly but is not yet approved for carcinoid syndrome [3][5] Company Overview - Crinetics Pharmaceuticals focuses on developing therapies for endocrine diseases and related tumors, with a strong emphasis on targeting G-protein coupled receptors (GPCRs) [8][9] - The company has a diverse pipeline with over 10 disclosed programs, including late-stage candidates for various endocrine conditions [9] Clinical Development - Paltusotine is in Phase 3 clinical development for carcinoid syndrome, with previous studies indicating significant reductions in common symptoms such as flushing and bowel movement frequency [5][6] - The upcoming presentations at NANETS will include details from the Phase 3 trial of paltusotine and a first-in-human study of the nonpeptide drug candidate CRN09682 [4][6]

Core Insights - Crinetics Pharmaceuticals reported a GAAP revenue of $1.0 million for Q2 2025, exceeding the consensus estimate of $0.61 million, but the GAAP net loss per share widened to $(1.23), larger than the anticipated $(1.08) per share, due to increased R&D and administrative expenses [1][5][6] Financial Performance - GAAP revenue for Q2 2025 was $1.0 million, a 150% increase from $0.4 million in Q2 2024 [2] - GAAP net loss per share was $(1.23), a 30.9% increase from $(0.94) in Q2 2024 [2] - Research and Development expenses rose to $80.3 million, up 37.8% from $58.3 million in Q2 2024 [2] - Selling, General & Administrative expenses doubled to $49.8 million from $24.8 million in Q2 2024 [2] - The company reported a net loss of $(115.6) million for the quarter, compared to $(74.1) million in Q2 2024 [1][6] Product Pipeline and Development - The company focuses on developing oral therapies for rare endocrine diseases, with lead products including paltusotine for acromegaly and carcinoid syndrome, and atumelnant for congenital adrenal hyperplasia and Cushing's disease [3][11] - Paltusotine's New Drug Application (NDA) review is on track, with a target FDA decision date of September 25, 2025 [7] - Atumelnant is in Phase 2 trials for CAH, with Phase 3 studies planned for both adult and pediatric populations [8] Strategic Initiatives - The company is preparing for its first commercial drug launch, focusing on regulatory approvals, clinical trial effectiveness, and building relationships with healthcare professionals [4][10] - The CrinetiCare platform is being established to support patient outreach and education ahead of the potential launch of paltusotine [10] Cash Position and Future Outlook - As of June 30, 2025, the company had $1.2 billion in cash, cash equivalents, and investments, expected to fund operations into 2029 [15] - Full-year cash use for 2025 is estimated between $340 to $370 million, reflecting readiness for commercial launch and ongoing late-stage trials [15] - Management did not provide formal guidance for future revenue or earnings, focusing instead on the upcoming FDA decision for paltusotine [14]

Company Overview and Financial Status - Crinetics has a strong financial position with $1.3 billion in cash, cash equivalents, and investments[31] - The company anticipates its first commercial launch this year and holds IP rights into the 2040s[31] Pipeline Programs and Focus - Crinetics is developing paltusotine, with a PDUFA date in September 2025, for acromegaly[27] - The company is developing CRN12755, a TSHR antagonist, for Graves' Hyperthyroidism and Graves' Orbitopathy (TED), with plans for an IND submission[123] - Crinetics is advancing CRN10329, an SST3 agonist, for Autosomal Dominant Polycystic Kidney Disease (ADPKD), with IND-enabling studies ongoing[150] - The company is developing CRN09682, a nonpeptide drug conjugate (NDC), targeting SST2-expressing tumors, currently in Phase 1/2 study[254] Market and Patient Reach - Graves' Hyperthyroidism affects over 3 million individuals in the US, with a significant portion developing TED[75] - ADPKD affects approximately 145,000 diagnosed patients in the US, with 50% developing end-stage kidney disease[130, 131] - The addressable patient population for Graves' Orbitopathy (TED) is up to approximately 170,000 incident cases[120]